Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.18 USD
+0.08 (0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.19 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Phathom Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 168 | 172 | 135 | 126 | 106 |
Income After Depreciation & Amortization | -167 | -172 | -135 | -126 | -106 |
Non-Operating Income | 8 | 2 | -2 | 1 | -145 |
Interest Expense | 42 | 27 | 7 | 5 | 4 |
Pretax Income | -202 | -198 | -144 | -129 | -255 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -202 | -198 | -144 | -129 | -255 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -202 | -198 | -144 | -129 | -255 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -165 | -170 | -131 | -124 | -106 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 4 | 2 | 0 |
Income After Depreciation & Amortization | -167 | -172 | -135 | -126 | -106 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.29 | 39.12 | 37.00 | 33.23 | 11.37 |
Diluted EPS Before Non-Recurring Items | -2.53 | -5.05 | -3.89 | -3.88 | -13.98 |
Diluted Net EPS (GAAP) | -3.93 | -5.05 | -3.89 | -3.88 | -22.45 |
Fiscal Year end for Phathom Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.68 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.17 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.52 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 70.39 | 35.66 | 31.70 | 30.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -69.87 | -35.66 | -31.70 | -30.08 |
Non-Operating Income | NA | 3.33 | 2.52 | 0.35 | 1.48 |
Interest Expense | NA | 13.03 | 10.11 | 9.62 | 9.22 |
Pretax Income | NA | -79.57 | -43.24 | -40.97 | -37.81 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -79.57 | -43.24 | -40.97 | -37.81 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -79.57 | -43.24 | -40.97 | -37.81 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 57.29 | 56.78 | 48.50 | 42.36 |
Diluted EPS Before Non-Recurring Items | NA | -0.80 | -0.76 | -0.84 | -0.89 |
Diluted Net EPS (GAAP) | NA | -1.44 | -0.76 | -0.84 | -0.89 |